Zacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPS

Analysts expect that Endocyte, Inc. (NASDAQ:ECYT) will post ($0.16) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Endocyte’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.16). Endocyte reported earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year-over-year growth rate of 38.5%. The firm is scheduled to report its next quarterly earnings results on Friday, March 9th.

On average, analysts expect that Endocyte will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($1.25) to ($1.23). For the next financial year, analysts expect that the company will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.02) to ($0.79). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Endocyte.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The firm had revenue of $0.03 million during the quarter. During the same quarter last year, the company posted ($0.21) earnings per share. Endocyte’s quarterly revenue was up .0% on a year-over-year basis.

Several analysts have recently issued reports on the company. ValuEngine lowered Endocyte from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Zacks Investment Research raised Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. Wedbush raised Endocyte from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $2.00 to $7.00 in a report on Tuesday, October 3rd. Finally, Cowen reissued a “hold” rating on shares of Endocyte in a report on Monday, October 2nd.

In related news, insider Philip S. Low bought 5,600 shares of Endocyte stock in a transaction dated Monday, November 13th. The shares were bought at an average cost of $4.84 per share, with a total value of $27,104.00. Following the acquisition, the insider now owns 283,005 shares in the company, valued at approximately $1,369,744.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 14.86% of the company’s stock.

Several hedge funds have recently made changes to their positions in ECYT. Dimensional Fund Advisors LP lifted its position in shares of Endocyte by 34.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 98,313 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 25,003 shares during the last quarter. Spark Investment Management LLC bought a new stake in shares of Endocyte during the 2nd quarter worth $177,000. LMR Partners LLP bought a new stake in shares of Endocyte during the 2nd quarter worth $196,000. Bank of New York Mellon Corp lifted its position in shares of Endocyte by 4.7% during the 1st quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after buying an additional 6,469 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Endocyte by 284.4% during the 1st quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after buying an additional 142,461 shares during the last quarter. Institutional investors and hedge funds own 17.67% of the company’s stock.

Endocyte (ECYT) opened at $5.12 on Friday. Endocyte has a 1-year low of $1.17 and a 1-year high of $6.55.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Expect Endocyte, Inc. (ECYT) to Announce -$0.16 EPS” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.com-unik.info/2017/12/03/zacks-brokerages-expect-endocyte-inc-ecyt-to-announce-0-16-eps.html.

About Endocyte

Get a free copy of the Zacks research report on Endocyte (ECYT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endocyte (NASDAQ:ECYT)

What are top analysts saying about Endocyte Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endocyte Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit